Epidemiology and Pathogenesis of Osteonecrosis of the Jaw

Overview

Journal Nat Rev Rheumatol

Specialty Rheumatology

Date 2011 Nov 30

PMID 22124271

Citations 69

Authors

Ian R Reid

Jillian Cornish

Affiliations

Soon will be listed here.

Abstract

Osteonecrosis of the jaw (ONJ) is defined as exposed bone in the oral cavity that persists despite appropriate therapy. Over the past decade, ONJ has been reported in about 5% of patients with cancer receiving high-dose intravenous bisphosphonates, and more recently in similar patients treated with denosumab, another potent inhibitor of osteoclastic bone resorption. The condition has also been described in patients treated with bisphosphonates for benign diseases, such as osteoporosis, but whether bisphosphonates or denosumab increase the incidence above that seen in untreated patients of comparable age and frailty is yet to be established. The pathogenesis of ONJ is uncertain: the toxic effects of bisphosphonates in a wide variety of cells could increase susceptibility to infections in the oral cavity or impair mucosal healing, and denosumab might interfere with monocyte and macrophage function. Local osteolysis is an important defense against infection on bone surfaces that is blocked by both bisphosphonates and denosumab. Preventive dentistry prior to high-dose antiresorptive therapy is a critical measure in cancer patients, but is not usually justified in patients with osteoporosis. The management of established ONJ lesions is problematic: the greatest success seems to come from vigorous antimicrobial therapy with judicious use of surgical debridement.

Citing Articles

Advances in mechanism and management of bone homeostasis in osteonecrosis: a review article from basic to clinical applications.

Xiang X, He H, He C Int J Surg. 2024; 111(1):1101-1122.

PMID: 39311934 PMC: 11745759. DOI: 10.1097/JS9.0000000000002094.

Novel Histopathological Findings of Micro Bone Fragments and Epithelial Response in the Oral Mucosa in Bisphosphonate-Related Osteonecrosis of the Jaw.

Koizumi G, Hayashi A, Takigawa A, Yamada R, Murata T, Shimizu K J Investig Med High Impact Case Rep. 2024; 12:23247096241258076.

PMID: 38818904 PMC: 11143842. DOI: 10.1177/23247096241258076.

Preparation and properties of a 3D printed nHA/PLA bone tissue engineering scaffold loaded with a β-CD-CHX combined dECM hydrogel.

Li S, Liu Z, Gao X, Cheng L, Xu Z, Li L RSC Adv. 2024; 14(14):9848-9859.

PMID: 38528932 PMC: 10961964. DOI: 10.1039/d4ra00261j.

Post biphosphonate mandible osteonecrosis: A case study and literature review.

Aboubacar B, Jumelle Z, Odero-Marah V, Romuald K, Laetitia O, Tarcissus K Oral Oncol Rep. 2023; 7.

PMID: 37846293 PMC: 10577950. DOI: 10.1016/j.oor.2023.100081.

Reduction of Inflammatory RANTES/CCL5 Serum Levels by Surgery in Patients with Bone Marrow Defects of the Jawbone.

Diederich J, Schwagten H, Biltgen G, Lechner J, Muller K Clin Cosmet Investig Dent. 2023; 15:181-188.

PMID: 37705670 PMC: 10496923. DOI: 10.2147/CCIDE.S417783.

References

Coxon F, Thompson K, Roelofs A, Ebetino F, Rogers M . Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone. 2008; 42(5):848-60. DOI: 10.1016/j.bone.2007.12.225. View

Ruggiero S, Mehrotra B, Rosenberg T, Engroff S . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62(5):527-34. DOI: 10.1016/j.joms.2004.02.004. View

Belibasakis G, Bostanci N, Hashim A, Johansson A, Aduse-Opoku J, Curtis M . Regulation of RANKL and OPG gene expression in human gingival fibroblasts and periodontal ligament cells by Porphyromonas gingivalis: a putative role of the Arg-gingipains. Microb Pathog. 2007; 43(1):46-53. DOI: 10.1016/j.micpath.2007.03.001. View

Han X, Lin X, Seliger A, Eastcott J, Kawai T, Taubman M . Expression of receptor activator of nuclear factor-kappaB ligand by B cells in response to oral bacteria. Oral Microbiol Immunol. 2009; 24(3):190-6. PMC: 2692067. DOI: 10.1111/j.1399-302X.2008.00494.x. View

Palaska P, Cartsos V, Zavras A . Bisphosphonates and time to osteonecrosis development. Oncologist. 2009; 14(11):1154-66. DOI: 10.1634/theoncologist.2009-0115. View

Khosla S, Burr D, Cauley J, Dempster D, Ebeling P, Felsenberg D . Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22(10):1479-91. DOI: 10.1359/jbmr.0707onj. View

Ripamonti C, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G . Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2008; 20(1):137-45. DOI: 10.1093/annonc/mdn526. View

Cartsos V, Zhu S, Zavras A . Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc. 2008; 139(1):23-30. DOI: 10.14219/jada.archive.2008.0016. View

Wessel J, Dodson T, Zavras A . Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg. 2008; 66(4):625-31. PMC: 2435366. DOI: 10.1016/j.joms.2007.11.032. View

10.

Harper R, Fung E . Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg. 2007; 65(3):573-80. DOI: 10.1016/j.joms.2006.10.076. View

11.

Reid I, Bolland M, Grey A . Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone. 2007; 41(3):318-20. DOI: 10.1016/j.bone.2007.04.196. View

12.

Favia G, Pilolli G, Maiorano E . Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone. 2009; 45(3):406-13. DOI: 10.1016/j.bone.2009.05.008. View

13.

Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L . Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377(9768):813-22. PMC: 3090685. DOI: 10.1016/S0140-6736(10)62344-6. View

14.

Black D, Reid I, Boonen S, Bucci-Rechtweg C, Cauley J, Cosman F . The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2011; 27(2):243-54. PMC: 3427916. DOI: 10.1002/jbmr.1494. View

15.

Hoefert S, Eufinger H . Relevance of a prolonged preoperative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg. 2010; 69(2):362-80. DOI: 10.1016/j.joms.2010.06.200. View

16.

Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S . Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med. 2006; 12(12):1372-9. DOI: 10.1038/nm1518. View

17.

Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis C . Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009; 27(32):5356-62. DOI: 10.1200/JCO.2009.21.9584. View

18.

Reid I, Miller P, Brown J, Kendler D, Fahrleitner-Pammer A, Valter I . Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. 2010; 25(10):2256-65. DOI: 10.1002/jbmr.149. View

19.

Marx R . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61(9):1115-7. DOI: 10.1016/s0278-2391(03)00720-1. View

20.

Stopeck A, Lipton A, Body J, Steger G, Tonkin K, De Boer R . Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28(35):5132-9. DOI: 10.1200/JCO.2010.29.7101. View